Balyasny Asset Management LLC Ironwood Pharmaceuticals Inc Transaction History

Balyasny Asset Management LLC

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$8.79 - $11.51 $72,499 - $94,934	-8,248 Reduced 27.58%	21,660 $247,000
Q3 2023 Nov 14, 2023	SELL	$8.25 - $11.35 $13.7 Million - $18.8 Million	-1,658,105 Reduced 98.23%	29,908 $288,000
Q2 2023 Aug 14, 2023	BUY	$10.1 - $11.6 $7.45 Million - $8.55 Million	737,277 Added 77.55%	1,688,013 $18 Million
Q1 2023 May 15, 2023	BUY	$10.37 - $12.56 $9.86 Million - $11.9 Million	950,736 New	950,736 $10 Million
Q2 2022 Aug 15, 2022	BUY	$11.05 - $12.72 $1.31 Million - $1.51 Million	118,980 New	118,980 $1.37 Million
Q3 2020 Nov 16, 2020	SELL	$8.99 - $10.74 $284,713 - $340,135	-31,670 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$9.14 - $11.97 $172,590 - $226,029	18,883 Added 147.67%	31,670 $327,000
Q1 2020 May 15, 2020	BUY	$8.58 - $14.01 $109,712 - $179,145	12,787 New	12,787 $129,000
Q3 2019 Nov 14, 2019	SELL	$8.59 - $10.96 $178,216 - $227,387	-20,747 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$9.8 - $12.89 $76,645 - $100,812	7,821 Added 60.51%	20,747 $227,000
Q1 2019 May 15, 2019	SELL	$8.27 - $12.73 $134,643 - $207,257	-16,281 Reduced 55.74%	12,926 $175,000
Q4 2018 Feb 14, 2019	BUY	$7.8 - $16.13 $227,814 - $471,108	29,207 New	29,207 $303,000
Q3 2018 Nov 14, 2018	SELL	$14.31 - $17.65 $249,165 - $307,321	-17,412 Closed	0 $0
Q2 2018 Aug 14, 2018	BUY	$11.83 - $16.2 $44,244 - $60,588	3,740 Added 27.36%	17,412 $333,000
Q1 2018 May 15, 2018	BUY	$11.13 - $13.63 $152,169 - $186,349	13,672 New	13,672 $211,000

238

162M

11.2M

9.1K

Ticker IRWD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 153,231,008
Market Cap $527M
Description
Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZE...

Get notified when there are updates to the investment portfolio of Balyasny Asset Management LLC, based on Form 13F filings with the SEC.

Stay updated on Balyasny Asset Management LLC with notifications on news.